| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen |
|
Medicine details |
|
| Medicine name | enzalutamide (Xtandi®) |
| Formulation | 40 mg capsule |
| Reference number | 779 |
| Indication | Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy |
| Company | Astellas Pharma Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/05/2013 |
| NICE guidance | |